Dr.Reddy's Laboratories Ltd (REDY.BO)
July 16 Indivior Plc's shares soared as much as 30 percent on Monday after a U.S. court blocked India's Dr.Reddy's Laboratories from selling copycat versions of the British drugmaker's bestselling opioid addiction treatment in the United States.
British drugmaker Indivior said on Wednesday its 2018 revenue and adjusted net income would come in below its previous forecast, hurt by the launch of generic versions of its bestselling opioid addiction treatment in the United States.
British drugmaker Indivior warned on Wednesday it would miss its full-year profit target as its best-selling opioid addiction drug faces new competitors in the United States, sending its shares down 37 percent.
* Best-seller's rapid market share loss to hit revenue by $25 mln
Indivior Plc got a breather on Friday as a U.S. court extended a restraining order blocking a rival from launching a generic version of its bestselling opioid addiction treatment in the United States.
* Update on Sublocade will be key to sentiment-Jefferies (Adds share move, analyst comments)
June 29 British drugmaker Indivior Plc said on Friday a U.S. court extended the restraining order blocking Indian pharmaceutical firm Dr.Reddy's Laboratories from launching a generic version of its bestselling opioid addiction treatment in the United States.
Shares in drugmaker Indivior rose on Monday after a U.S. Court granted a temporary restraining order blocking Dr. Reddy's Laboratories from launching a generic version of Indivior's best-selling opioid addiction treatment.
* NSE index ended 0.09 pct higher, BSE index closed up 0.06 pct
May 22 Indian shares ended slightly higher on Tuesday, driven by gains in Dr. Reddy's Laboratories Ltd and State Bank of India (SBI) following their quarterly results.